John Martin - 2010 CEO Pay

John C. Martin

John Martin - Gilead Sciences

Total Compensation: $14.2 million

Details: John Martin's compensation was down a little in 2010 from 2009, when his package was worth just under $14.7 million; last year, it was $14.2 million. Martin earned a salary of a little more than $1.3 million last year--up from $1.24 million in 2009. He also received stock and option awards of roughly $10.5 million--down from the previous year, when he snagged more than $11.1 million.

As Dow Jones notes, Gilead is known for its HIV drugs and saw its net income rise 10 percent to $2.9 billion on revenue growth of 13 percent to $7.9 billion.

Gilead Sciences News:
Truvada fails trial to prevent HIV in women
Who's the biggest HIV drug seller of all?

John Martin - 2010 CEO Pay

Suggested Articles

New models are needed to assess the value of gene and cell therapies and provide reimbursement, Novartis CEO Vas Narasimhan says.

With stocks tumbling and a price-fixing lawsuit hanging over its head, Mylan’s future is looking spooky. Could a new acquisition help turn the tide?

AbbVie is rolling out psoriasis drug Skyrizi after an approval last month, and it's offered Humira discounts in payer negotiations to support the launch,…